Analysts Anticipate Novartis AG (NYSE:NVS) Will Announce Earnings of $1.64 Per Share


Share on StockTwits

Equities analysts expect Novartis AG (NYSE:NVS) to post earnings of $1.64 per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Novartis’ earnings. Novartis posted earnings per share of $1.55 in the same quarter last year, which would indicate a positive year over year growth rate of 5.8%. The firm is scheduled to announce its next quarterly earnings report before the market opens on Tuesday, April 27th.

On average, analysts expect that Novartis will report full-year earnings of $6.44 per share for the current financial year, with EPS estimates ranging from $6.35 to $6.55. For the next fiscal year, analysts anticipate that the firm will post earnings of $6.88 per share, with EPS estimates ranging from $6.71 to $7.09. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Novartis.

Novartis (NYSE:NVS) last released its quarterly earnings results on Monday, January 25th. The company reported $1.34 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.37 by ($0.03). Novartis had a return on equity of 24.39% and a net margin of 14.71%. The business had revenue of $12.77 billion during the quarter, compared to the consensus estimate of $12.86 billion. During the same period in the previous year, the company posted $1.32 EPS. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year.

A number of equities analysts recently weighed in on the company. Morgan Stanley reiterated an “overweight” rating on shares of Novartis in a research report on Tuesday, February 2nd. Cowen lowered Novartis from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $110.00 to $105.00 in a research report on Monday, February 1st. Argus reiterated a “hold” rating on shares of Novartis in a research report on Tuesday, March 16th. Societe Generale reiterated a “buy” rating on shares of Novartis in a research report on Tuesday, March 23rd. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Novartis in a research report on Friday, January 15th. They issued a “buy” rating for the company. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the company’s stock. Novartis currently has an average rating of “Hold” and a consensus target price of $108.50.

A number of institutional investors have recently made changes to their positions in NVS. Phoenix Wealth Advisors purchased a new stake in Novartis in the 4th quarter worth about $27,000. Regent Peak Wealth Advisors LLC purchased a new stake in shares of Novartis during the 4th quarter worth about $34,000. Addison Advisors LLC purchased a new stake in shares of Novartis during the 4th quarter worth about $40,000. Veriti Management LLC purchased a new stake in shares of Novartis during the 4th quarter worth about $42,000. Finally, Hoese & Co LLP purchased a new stake in shares of Novartis during the 4th quarter worth about $42,000. 9.86% of the stock is owned by hedge funds and other institutional investors.

Shares of NVS stock opened at $86.30 on Thursday. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.49. Novartis has a fifty-two week low of $77.04 and a fifty-two week high of $98.52. The stock has a market capitalization of $197.51 billion, a P/E ratio of 27.93, a P/E/G ratio of 1.76 and a beta of 0.59. The stock has a 50-day simple moving average of $86.31 and a 200 day simple moving average of $88.58.

The firm also recently disclosed an annual dividend, which was paid on Monday, March 15th. Investors of record on Friday, March 5th were paid a $3.3784 dividend. This is an increase from Novartis’s previous annual dividend of $3.04. This represents a yield of 2.2%. The ex-dividend date of this dividend was Thursday, March 4th. Novartis’s dividend payout ratio is currently 39.69%.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.

Featured Story: What economic reports are most valuable to investors?

Get a free copy of the Zacks research report on Novartis (NVS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.